Dalbavancin

DALVANCE FDA Approval Acute Bacterial Skin Structure Infections in Pediatric

Details : The 5 patients in the age group birth to less than 3 months of age were not included in the efficacy analyses since they were enrolled with expanded inclusion criteria and only received the single-dose DALVANCE regimen.

Product Name : Dalvance

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

July 23, 2021

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

02

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Dalbavancin

Therapeutic Area : Cardiology/Vascular Diseases

Study Phase : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treat...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Endocarditis.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

May 11, 2017

Lead Product(s) : Dalbavancin

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

03

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Susp...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Methicillin-Resistant Staphylococcus aureus.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

June 28, 2016

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

04

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase I

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacteria...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bacterial Infections.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

February 23, 2016

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

05

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyeli...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteomyelitis.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

February 18, 2016

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

06

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Community-Acquired Pneumonia.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

October 21, 2014

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

07

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure I...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Abscess.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

May 01, 2014

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

08

AbbVie Inc

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase I

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Age...

Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bacterial Infections.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Inapplicable

September 19, 2013

Lead Product(s) : Dalbavancin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable